Company / Cash & Equivalents
IGC Pharma, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$405.0K
FY2025
5-year range
$405.0K / $10.5M
FY2021-FY2025
Trend
-66.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 3 consecutive years, from $10M in FY2022 to $405,000 in FY2025.
Based on SEC 10-K filings.
$405,000 in FY2025 with a 5-year CAGR of -56.4%.
Declined from $3M to $405,000 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -66.2%
- 5-Year CAGR
- -56.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- IGC Pharma, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -56.4%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 66.2% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $405.0K | -66.2% |
| FY2024 | $1.2M | -62.5% |
| FY2023 | $3.2M | -69.4% |
| FY2022 | $10.5M | +44.1% |
| FY2021 | $7.3M | -71.7% |
| FY2020 | $25.6M | +1444.6% |
| FY2019 | $1.7M | +208.2% |
| FY2018 | $538.0K | -63.9% |
| FY2017 | $1.5M | +80.8% |
| FY2016 | $824.5K | -19.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026